Fosun Pharma Subsidiary Fosun Wanbang Enters into R&D and Commercialization Agreement with Junshi Biosciences for Roconkibart (Anti-IL-17A Monoclonal Antibody) in Greater China
Junshi Biosciences
Innovative Drug Developer
Fosun Pharmaceutical
Healthcare Industry Group
Fosun Pharmaceutical (stock codes: 600196.SH; 02196.HK) announced that its controlling subsidiary, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has recently signed a licensing agreement with Junshi Biosciences (stock codes: 688180.SH, 01877.HK). The two parties have reached a collaboration on the development, registration, manufacturing, and commercialization of surucimab (JS005, an anti-IL-17A monoclonal antibody) in the Greater China region (Mainland China, Hong Kong, Macao, and Taiwan).
Ruokacibai monoclonal antibody is a specific anti-IL-17A monoclonal antibody independently developed by Junshi Biosciences. IL (interleukin)-17A is a pleiotropic cytokine, and its dysregulated secretion is closely associated with the pathogenesis and progression of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. Ruokacibai monoclonal antibody binds with high affinity to both the IL-17A homodimer and the IL-17A/IL-17F heterodimer, selectively blocking the interaction between IL-17A and its receptor complex IL-17RA/IL-17RC. This inhibition prevents the activation of downstream signaling pathways and the release of inflammatory mediators, thereby effectively alleviating the symptoms of autoimmune diseases.
Rociperceptamab has completed its Phase III registrational clinical study in China among adult patients with moderate-to-severe plaque psoriasis, demonstrating excellent efficacy and safety. In the 150 mg dose group, the PASI 90 response rate reached 91% at Week 16, and the PASI 100 response rate reached 65% at Week 52. In December 2025, the National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for rociperceptamab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Currently, all participants in the Phase II clinical trial of rociperceptamab for the treatment of active ankylosing spondylitis (AS) have completed study follow-up.
Li Jing
Co-President of Fosun Pharmaceutical, Chairman of Jiangsu Wanbang Biopharmaceuticals
Autoimmune diseases represent a significant area of unmet clinical need and are one of the core therapeutic areas of strategic focus for Fosun Pharmaceutical. This strategic collaboration with Junshi Biosciences is also a key initiative by Fosun Pharmaceutical to continuously enrich its high-value pipeline portfolio in the field of immunology and inflammation. In Phase III clinical trials, revocizumab demonstrated excellent efficacy data, showing rapid and sustained disease control in indications such as psoriasis. Fosun Pharmaceutical has established a mature clinical development and commercialization system in the field of immunology and inflammation. Moving forward, we will fully leverage our respective strengths to accelerate the development and commercialization of revocizumab in the Greater China region, ensuring that this innovative drug with breakthrough therapeutic potential benefits more patients at an earlier stage.
Dr. Zou Jianjun
General Manager and Chief Executive Officer of Junshi Biosciences
This strategic collaboration with Fosun Pharmaceutical represents a key deepening of our strategic layout in the field of autoimmune diseases. With years of dedicated engagement in this sector, Fosun Pharmaceutical has established a specialized commercialization team and a mature, efficient market system, which will inject strong momentum into the rapid advancement of ruokacibai monoclonal antibody. This partnership not only validates our company’s innovative strength in the autoimmune domain but also marks a milestone leap as both parties join hands to address patient expectations through innovation. We look forward to accelerating the clinical development and commercialization of ruokacibai monoclonal antibody in the Greater China region through this deep synergy, thereby bringing new hope for life to more patients in urgent need of effective treatments.
About Fosun Pharmaceutical
Fosun Pharmaceutical (Stock Codes: 600196.SH; 02196.HK), established in 1994, is an innovation-driven global pharmaceutical and healthcare industry group. Guided by our mission to “enable every family to enjoy health,” we are deeply committed to our pharmaceutical business, with a strategic focus on innovative drugs. We directly operate businesses in medical devices and diagnostics, as well as healthcare services, and cover the pharmaceutical commercial sector through our associate company, Sinopharm Holdings, thereby building a comprehensive ecosystem spanning the entire pharmaceutical and healthcare industry chain.
Driving Innovation, Deepening Global Presence. Fosun Pharmaceutical has established an open, globalized innovation and R&D system. Focusing on unmet clinical needs, we have strategically positioned ourselves in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into chronic diseases and rare diseases to build a product pipeline and comprehensive solutions with long-term competitiveness. Meanwhile, Fosun Pharmaceutical continues to strengthen its core technology platforms, including antibodies and ADCs, small molecules, and cell therapies, while actively exploring frontier technologies such as radiopharmaceuticals and small nucleic acids to enhance early-stage innovation capabilities and accelerate the translation of scientific achievements. Our innovative products are now sold in more than 90 countries and regions worldwide, covering markets in China, the United States, Europe, Africa, India, and Southeast Asia.
Looking ahead, guided by the strategy of “innovation-led, deep internationalization, and full embrace of AI,” Fosun Pharmaceutical will uphold its core values of “caring for life, continuous innovation, pursuit of excellence, and win-win cooperation,” striving to become a globally leading integrator of medical innovation. The company is committed to making the benefits of medical innovations accessible to more patients worldwide and contributing to the protection of human health.
About Junshi Biosciences
Junshi Biosciences (688180.SH, 1877.HK), established in December 2012, is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. Leveraging its exceptional drug discovery capabilities, robust biotechnology R&D strength, and large-scale manufacturing capacity, the company has successfully developed a portfolio of internationally competitive products and established a tiered research pipeline covering therapeutic areas such as oncology, autoimmune diseases, chronic metabolic disorders, and infectious diseases. Its innovative endeavors span cutting-edge modalities including monoclonal antibodies, small molecules, antibody-drug conjugates (ADCs), bispecific/multispecific antibodies, fusion proteins, nucleic acid-based therapeutics, and vaccines. To date, the company has commercialized five products domestically or overseas, including toripalimab (Tuoyi), a PD-1 inhibitor independently developed in China, which has been approved for marketing in more than 40 countries and regions worldwide, including China, the United States, and Europe.®）。
Junshi Biosciences is committed to its mission of “making world-class, trustworthy innovative medicines accessible to patients.” Rooted in China with a global footprint, the Company currently employs nearly 3,000 people worldwide, primarily located in Maryland (USA), and Shanghai, Suzhou, Beijing, and Guangzhou (China).
Contact Information
Media:pr@fosunpharma.com
Investors:ir@fosunpharma.com
